This site is your gateway to information about stem cell treatment for spinal cord injuries (SCI) using Beike Biotechnology Company’s adult stem cells. This treatment is offered as an alternative treatment for patients who do not want to (or who cannot) wait the ten years it will take for umbilical cord blood stem cell treatment to be approved by the FDA in the United States or in their home country.
As a biotechnology company at the cutting edge of regenerative medicine, Beike is dedicated to developing technologies and protocols for safe, effective treatments utilizing adult stem cells – with a focus on umbilical cord and cord blood-derived stem cell therapy. We are partners with leading scientists, and over 250 doctors in more than 30 leading hospitals across China who specialize in delivering stem cell therapy to treat neurological, vascular and liver diseases as well as other ailments.
Our mission is to be the world leader in stem cell research and clinical treatment, to make comprehensive cellular therapy accessible and cost-effective to those in need, and to improve every patient’s quality of life. Beike Biotech has developed specialized treatment protocols for many kinds of ailments and injuries – used by doctors throughout China to treat more than 200 patients every month. Beike’s stem cells have been used in nearly 20,000 stem cell transplants since 2001 and our network of scientists has published over 100 articles in China’s leading bioscience journals.
About Beike
Beike (pronounced Bay-Ka) is a Chinese biotechnology company headquartered in Shenzhen (near Hong Kong) and in Taizhou in the China Medical City. The company was founded with capital from Beijing University, Hong Kong University of Science and Technology, and Shenzhen City Hall. The formation of the company was also supported with grants from the China State National Fund. In total, Beike has received over US$6 million in Chinese government grants.
Beike is a private company but operates with support from various departments of the Chinese government. Beike’s stem cell research and clinical applications were developed over a period of several years beginning in the late 1990′s primarily by Zhengzhou University.
Beike’s network of over 60 PhDs from Beijing University, No. 3 Army Medical University, Zhongshan Medical University and Guiyang Medical College has contributed to Beike’s treatment technologies. Beike’s full-time scientific staff includes graduates from leading western universities including Stanford, University of Minnesota and UCLA.
After conducting trials for human safety and effectiveness, doctors in Zhengzhou proceeded to treat the first ALS (Amyotrophic Lateral Sclerosis, also known as Motor Neuron Disease) patient in 2001. From 2001 to 2005, over 200 patients were treated in various studies in order to determine the efficacy of the treatment for end-stage patients and otherwise incurable diseases.
Beike was incorporated in July 2005 after the collaborating scientists had established the safety and efficacy of their technology.
Ethical Stem Cell Source
Beike’s umbilical cord blood stem cells are derived from healthy donors who are carefully screened for transmissible diseases. The samples are additionally screened by government appointed blood banks and Beike’s specialized laboratories. The stem cells are used withing 7-10 days after birth – never frozen – and are utilized at some of Asia’s best hospitals by qualified physicians.
